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Abstract
Background: Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and
CFS1R. This multicenter phase 1/2 study evaluated the maximum tolerated dose (MTD), safety, and clinical activity
of pacritinib in patients with myelofibrosis (MF) and other advanced myeloid malignancies.
Methods: In the phase 1 dose-escalation part of the study, 43 adults with advanced myeloid malignancies received
pacritinib 100 to 600 mg once daily (QD). In the phase 2 part of the study, 31 adults with refractory or intermediate- or
high-risk newly diagnosed MF and any degree of cytopenia received pacritinib 400 mg QD. The primary endpoint
is a ≥35% reduction in spleen volume at week 24 as determined by magnetic resonance imaging.
Results: Five patients (11.6%) experienced a dose-limiting toxicity during cycle 1 of phase 1. The clinical benefit
rate was 86.0% (13 patients achieving clinical improvement and 24 patients having stable disease). The MTD
was established at 500 mg QD, and the recommended phase 2 dose was 400 mg QD. In phase 2, the primary
endpoint was achieved by 23.5% of evaluable patients (4/17), with 47.4% (9/19) achieving a ≥50% spleen length
reduction at week 24 as measured by physical examination. At week 24, 38.9% of evaluable patients (7/18)
achieved a ≥50% decrease in MF Quality of Life and Symptom Assessment total score. Gastrointestinal toxicities
were the most common adverse events and were predominantly grade 1/2 in severity. Grade 3/4 anemia was
reported in 5/31 patients and grade 3/4 thrombocytopenia was reported in 3/31 patients. The most frequent
AEs considered to be treatment related were diarrhea (28/31), nausea (15/31), vomiting (9/31), and fatigue (4/31).
Grade 3 treatment-related AEs were reported in seven patients (22.6%), four of whom had diarrhea. No grade 4/5
treatment-related AEs were reported. No leukopenia, neutropenia, or lymphopenia were reported.
Conclusions: Pacritinib was well tolerated and demonstrated clinical activity in MF. The study suggests that
pacritinib has unique characteristics, namely a lack of substantial myelosuppression and manageable side effects,
making it an attractive target for further evaluation in MF.
Trial registration: Retrospectively registered at www.clinicaltrials.gov (#NCT00719836) on July 20, 2008.
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Background
Aberrant activation of the JAK/STAT pathway plays a
central role in myeloproliferative neoplasms (MPNs), a
group of heterogeneous diseases including polycythemia
vera (PV), essential thrombocythemia (ET), and chronic
idiopathic myelofibrosis (MF) [1, 2]. The discovery of a
dominant gain-of-function mutation in the JAK2 gene
(JAK2V617F) in most patients with PV, and 30–60% of
patients with ET or MF allowed identification of JAK2
as a new therapeutic target for these disorders [3–6].
MPN patients negative for JAK2V617F may display mu-
tations in the thrombopoietin receptor gene (MPL) [7]
or the calreticulin gene (CALR) [8], which may also
lead to dysregulated JAK/STAT-dependent processes.
Greater understanding of the JAK/STAT pathway and
its role in MPNs has led to the development of thera-
peutic JAK inhibitors. These agents are not mutation
specific and are effective in MPN patients with and
without the JAK2 mutation [9].
FMS-like tyrosine kinase 3 (FLT3) mutations that in-
volve internal tandem duplications of the juxtamembrane
domain-coding sequence are found in 20–30% of patients
with acute myeloid leukemia (AML), typically in de novo
AML, and are associated with poor clinical outcomes
[10–12]. Upregulation of FLT3 may also be involved in
driving the abnormal production of peripheral platelets,
characteristic of MF [13].
Pacritinib (SB1518) is a kinase inhibitor with specifi-
city for JAK2, FLT3, IRAK1, and CFS1R [14–16]; it does
not have specificity for JAK1 at pharmacologically-
relevant levels [14]. Pacritinib demonstrated a favorable
safety and pharmacological activity profile in preclinical
hematologic malignancy models [17, 18]. The objectives
of this multicenter phase 1/2 study were to determine
the maximum tolerated dose (MTD), pharmacokinetics,
safety, and clinical activity of pacritinib in patients with
MF and other advanced myeloid malignancies.
Methods
This clinical study included a phase 1 dose escalation
component to establish the MTD of pacritinib in pa-
tients with advanced myeloid malignancies, followed by
an open-label, single-arm phase 2 component to assess
the clinical activity (based on spleen response rate) and
tolerability of pacritinib administered at the recom-
mended dose in patients with MF.
Ethics, consent, and data analysis
The study was conducted at three centers in the USA
between June 2008 and October 2011 in accordance with
the Declaration of Helsinki, International Conference on
Harmonization guidelines, and relevant laws and regula-
tions. The protocol was approved by the institutional re-
view boards at each study site. Written informed consent
was obtained from all patients prior to participation. Data
collection, data entry, and database lock were performed
by S*BIO Pte Ltd (the original study sponsor) and data
analysis was performed by CTI BioPharma Corp. (who
acquired pacritinib in 2012). All authors had access to
primary clinical trial data.
Patients
Patients were eligible for inclusion in phase 1 if they had
a histologically confirmed myeloid malignancy and had
failed standard therapies or were not candidates for
palliative therapies. Eligible malignancies included AML;
chronic myeloid leukemia (CML) in accelerated or blast
phase; high-risk myelodysplastic syndrome (refractory
anemia with 5–19% bone marrow blasts or chronic mye-
lomonocytic leukemia with >5% bone marrow blasts);
and advanced MF with ≥1 poor prognostic feature
(hemoglobin <10 g/dL, platelets <100 × 109/L, white
blood cells <4 or >30 × 109/L, or symptomatic spleno-
megaly ≥10 cm below the left costal margin). Patients
were eligible for inclusion in phase 2 if they had MF (in-
cluding post-ET [PET]-/post-PV [PPV]-MF) that had re-
lapsed or was not well controlled with standard therapy
and had splenomegaly ≥5 cm below the costal margin.
Patients were also eligible if they had newly diagnosed
MF classified as intermediate- or high-risk [19] and were
not suitable for standard therapy. In both components
of the study, patients were required to be aged ≥18 years
with Eastern Cooperative Oncology Group performance
status (ECOG PS) 0–2; adequate liver and renal func-
tion; corrected QTc interval ≤0.47 s (Bazett formula); a
2-week window from prior disease-directed therapy with
recovery from prior toxicities to grade ≤1; and a 1-week
window from prior hydroxyurea and CYP3A4 inducer/
inhibitor treatment. Patients with uncontrolled intercur-
rent illness, concurrent malignancy, HIV, or active hepa-
titis A, B, or C were excluded, as were those who were
pregnant, lactating, or unwilling/unable to undergo a
magnetic resonance imaging (MRI) scan (phase 2 only).
Study design and treatment
Phase 1 was a 3 + 3 dose-escalation study. Three to six
patients were enrolled at each dose level, depending
upon observed dose-limiting toxicities (DLTs) in the co-
hort. Each patient participated in only one cohort. Oral
pacritinib was administered to the first cohort at 100 mg
once daily (QD) for 25 consecutive days in a 28-day
cycle in cycle 1, with 3 days of rest for pharmacokinetic
(PK) sampling, followed by continuous 28-day dosing
for the remaining cycles. Subsequent cohorts received
escalating pacritinib dose levels of 150, 200, 300, 400,
500, and 600 mg QD. All patients at each dose level
were observed through the end of the first cycle before
the next dose level could begin treatment.
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Each patient enrolled in phase 1 was allowed two dose
escalations at the investigator’s discretion and with the
sponsor’s approval. Those who had completed ≥3 treat-
ment cycles without disease progression could escalate
to the last dose level cleared as tolerable. Once the
MTD was reached, patients treated at lower dose levels
(including those who had undergone one previous dose
escalation) were permitted to escalate to the recom-
mended dose.
A DLT was defined as a grade 3/4 non-hematologic
adverse event (AE), a clinically significant grade 4
hematologic AE that persisted >28 days in the absence
of active hematologic malignancy with bone marrow
involvement, or grade 4 febrile neutropenia/granulocyto-
penia during cycle 1 that was possibly, probably, or
definitely related to the study drug. In addition, any
other clinically significant events that resulted in study
drug interruption and/or dose reduction could be con-
sidered a DLT. Grade 3 diarrhea or vomiting were only
considered DLTs if they persisted for >7 days despite
treatment. Fatigue was only considered a DLT if it was
grade 4 and persisted for >2 weeks. In patients with
grade 2 alanine aminotransferase/aspartate aminotrans-
ferase elevations at baseline, elevations were only consid-
ered DLTs if they exceeded three times the baseline level
and were confirmed 1 week later. Recurrence of prior
grade 3 hyperuricemia was not considered a DLT.
Phase 2 dose selection was based on exposure, safety,
pharmacodynamic, and clinical benefit data from phase
1. In phase 2, patients received pacritinib 400 mg QD
without interruption in a 28-day cycle.
Treatment was able to be withheld for up to 2 weeks
for treatment-emergent AEs. After toxicity resolution,
patients could resume treatment at the same or a re-
duced dose at the discretion of the investigator after
discussion with the sponsor (Additional file 1: Table S1).
Up to two dose reductions were allowed; however, re-
escalation was not permitted.
Two forms of pacritinib were developed. The study
was initiated with the hydrochloride (HCl) salt formula-
tion, which was also used for non-clinical and early clin-
ical development. A citrate salt formulation containing
the same active moiety was later designed to improve
the physical stability of the product. Six new patients
were enrolled in phase 1 and received pacritinib citrate
salt 200 mg QD. Patients enrolled in phase 1 were sub-
sequently switched to the citrate salt and all patients
enrolled in phase 2 received the citrate salt.
Study procedures
At screening/baseline, patients underwent a medical
history, physical examination, vital sign assessment,
ECOG PS assessment, electrocardiogram, and assess-
ment of hematologic parameters and blood chemistry.
Hematology/blood chemistry, physical examinations,
and vital sign assessments were performed throughout
treatment. Toxicity was assessed using the National
Cancer Institute Common Terminology Criteria for
Adverse Events (NCIC-CTCAE), version 3.0, with rela-
tionship to treatment assigned by the investigator and
were recorded from the first dose of pacritinib until
30 days after the last dose. Bone marrow biopsy and/or
aspirate samples were drawn at baseline, on day 1 of
cycle 4 and cycle 10, as clinically indicated, and at the
termination visit. Disease response and progression
were determined using the relevant International
Working Group (IWG) criteria [20–23].
In phase 1, full PK sampling was performed on days 1
and 15 of cycle 1 and day 1 of cycle 2. Trough PK sam-
ples were drawn prior to dosing on days 8 and 22 of
cycle 1 and at 24, 48, and 72 h after dosing on day 25 of
cycle 1. A sample was collected before dosing on day 1
of cycles 4, 7, and 10. Pacritinib concentrations were de-
termined using a validated liquid chromatography/tan-
dem mass spectrometry method. An analysis of clinical
exposures from the HCl and citrate salts of pacritinib
was performed comparing Day 1 PK data from 12
patients who received the HCl salt formulation in the
200 mg cohorts of this study and two other pacritinib
studies [NCT00741871 and NCT00745550]) with six pa-
tients in the 200 mg cohort of this study who received
the citrate salt formulation.
In phase 2, abdominal MRI to assess spleen and liver
volume was performed on day 1 of cycles 1, 4, and 7 and
then day 1 of every third cycle through cycle 25. Spleen
size (length) was also assessed by manual palpation with
each scheduled physical examination. The phase 2 study
protocol was amended in September 2009 to include the
MF Quality of Life and Symptoms Assessment Tool.
The tool was derived from the MF Symptom Assess-
ment Form [24] and rated disease-related symptoms
(worst fatigue, early satiety, abdominal pain or discom-
fort, night sweats, itching, and bone pain) and overall
quality of life on a scale of 0 (absent) to 10 (worst im-
aginable). The instrument was administered pre-dose on
day 1 of cycles 1, 2, 4, 7, and 10 and then on day 1 of
every third cycle through cycle 25.
Statistical analysis
The primary objective of phase 1 was to establish the
MTD of pacritinib in patients with advanced myeloid
malignancies, defined as the highest dose level at which
no more than one out of six patients in the cohort
experienced a DLT during cycle 1 (25 days) of therapy.
The DLT-evaluable population included all patients
who completed at least 18 of the 25 originally assigned
doses in cycle 1, or those who did not complete the re-
quired number of assigned doses and had a DLT.
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Secondary objectives in phase 1 of the study included
safety and PK analysis. Clinical benefit rate was
assessed as an exploratory endpoint, defined as the pro-
portion of patients who experienced a complete re-
sponse, partial response, clinical improvement, or
stable disease (SD) during the study.
The primary endpoint of the phase 2 component was
the proportion of the efficacy population who achieved a
≥35% reduction in spleen volume from baseline at week
24, as measured by MRI. Spleen response rate was also
assessed in terms of a ≥35% reduction in spleen volume
by MRI up to week 24 and end of treatment and as a
≥50% reduction in spleen length by physical examination
up to week 24 and end of treatment. Duration of re-
sponse was not analyzed due to limitations in the pro-
portion of responders. An exploratory endpoint was the
proportion of patients with a ≥50% reduction in MF
Quality of Life and Symptoms Assessment Tool at week
24 compared with baseline.
The planned sample size of 29 patients for the phase 2
component provided 80% power to detect a spleen re-
sponse rate of ≥30% versus the null hypothesis of a re-
sponse rate of ≤10%, with α = 0.05 (two-sided). The
efficacy-evaluable population included those patients
with a baseline and corresponding follow-up value. The
safety population included all enrolled patients who re-




In phase 1, 43 patients with advanced myeloid malignan-
cies (MF: n = 36; AML: n = 7) were treated with pacriti-
nib at doses ranging from 100 to 600 mg QD. Subject
demographics and baseline characteristics are shown in
Table 1.
The majority of patients had splenomegaly (n = 28;
65.1%). At baseline, grade 2 or higher anemia and
thrombocytopenia were reported in 28 (65.1%) and 21
(48.8%) patients, respectively. Of the 43 patients, 18
(41.9%) completed the study and 25 (58.1%) discontin-
ued the study, primarily because of disease progression
(n = 9) and the sponsor’s decision to terminate the study
for financial reasons (n = 7).
DLTs and MTD
All 43 patients enrolled in phase 1 were evaluable for DLT
assessment. Overall, five patients (11.6%) experienced a
DLT during cycle 1 (Table 2). Diarrhea that was consid-
ered to be a DLT was reported in one patient at each of
the following dose levels: 300, 500, and 600 mg. One
patient in the 150 mg cohort experienced grade 3 QTc
prolongation (QTc of 460 ms at screening, 491 ms on
cycle 1 day 1, 504 ms on cycle 1 day 15, and 519 ms on
cycle 1 day 22 [last assessment available]). The patient had
Table 1 Baseline characteristics and demographics for patients enrolled in phase 1 (n = 43)
Pacritinib
100 mg 150 mg 200 mg 300 mg 400 mg 500 mg 600 mg All patientsa
n = 3 n = 6 n = 9 n = 6 n = 6 n = 7 n = 6 n = 43
















Male, n (%) 2 (66.7) 5 (83.3) 7 (77.8) 3 (50.0) 2 (33.3) 4 (57.1) 4 (66.7) 27 (62.8)
ECOG PS, n (%)
0 0 2 (33.3) 5 (55.6) 4 (66.7%) 3 (50.0) 4 (57.1) 0 18 (41.9)
1 2 (66.7) 2 (33.3) 4 (44.4) 1 (16.7) 2 (33.3) 2 (28.6) 5 (83.3) 18 (41.9)
2 1 (33.3) 2 (33.3) 0 1 (16.7) 1 (16.7) 1 (14.3) 1 (16.7) 7 (16.3)
















Current malignancy type, n (%)
AML 0 3 (50.0) 0 0 3 (50.0) 0 1 (16.7) 7 (16.3)
JAK2 mutationb, n/N (%) – 1/3 (33.3) – – 2/3 (66.7) – 1/1 (100) 4/7 (57.1)
Myelofibrosis 3 (100.0) 3 (50.0) 9 (100.0) 6 (100.0) 3 (50.0) 7 (100.0) 5 (83.3) 36 (83.7)
JAK2 mutationb, n/N (%) 2/3 (66.7) 2/3 (66.7) 8/9 (88.9) 5/6 (83.3) 3/3 (100) 5/7 (71.4) 4/5 (80.0) 29/36 (80.6)
Median prior systemic therapies,
n (range)
1.0 (0–4) 3.0 (2–4) 1.0 (0–4) 2.0 (1–4) 2.0 (1–4) 2.0 (0–4) 3.0 (1–4) 3.0 (0–4)


















a86% of patients were white
bAll JAK2 mutations were V617F
AML acute myeloid leukemia, ECOG PS Eastern Cooperative Oncology Group Performance Status, MDS myelodysplastic syndrome
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baseline atrial fibrillation, a history of inferior myocardial
infarction and right bundle branch block, hypokalemia
and was receiving amiodarone, solifenacin, and flucona-
zole. Pacritinib was discontinued and the QTc prolonga-
tion resolved. One patient in the pacritinib 600 mg cohort
experienced six distinct grade 1 or 2 events that were indi-
vidually assessed as not serious but were considered as
DLTs when taken together (Table 2). Relevant prior
history included prostate cancer, renal cell carcinoma-post
partial nephrectomy, cataract surgery, celiac sprue, and
vertigo. Pacritinib was interrupted and the dosage was
reduced to 400 mg QD. Nausea and vomiting resolved
with antiemetic therapy. Dizziness and the decrease in
performance status resolved; however, blurred vision and
gait disturbance were ongoing at the end of study.
The MTD of pacritinib was determined to be 500 mg
QD. Although only one of seven patients in the 500 mg
QD cohort experienced a DLT, two discontinued treat-
ment due to AEs, three required dose interruptions,
three required dose reductions, and three experienced a
serious AE (SAE). Therefore, pacritinib 400 mg QD was
selected as the recommended phase 2 dose.
Safety
Table 3 summarizes treatment-emergent AEs occurring
in ≥10% of patients in phase 1. The most frequent AEs
were gastrointestinal in nature and were mainly grades 1
or 2 in severity. There were no discernible trends ob-
served across dose cohorts in the incidence of AEs; how-
ever, diarrhea and nausea were reported more frequently
in patients receiving doses ≥400 vs <400 mg. Anemia
and thrombocytopenia were the most frequent grade 3/4
AEs, occurring in seven (16.3%) and 6 (14.0%) patients,
respectively. Eight patients discontinued pacritinib
because of an AE, three of which were considered to be
treatment related (grade 3 prolonged QTc [resolved],
grade 3 fatigue [ongoing at the end of follow-up], and
grade 3 increased transaminases [resolved]. Dose inter-
ruptions or reductions due to AEs occurred in 18 and 9
patients, respectively.
The most frequent AEs considered to be treatment re-
lated were diarrhea (65.1%), nausea (34.9%), vomiting
(23.3%), and thrombocytopenia (11.6%). Across dose co-
horts, larger proportions of patients reported treatment-
related AEs in cohorts administered doses ≥400 mg.
Grade 3 and 4 treatment-related AEs were reported in
nine patients (20.9%) and two patients (4.7%), respect-
ively. No grade 4 gastrointestinal AEs occurred.
SAEs occurred in 19 patients (44.2%) during phase 1
(Additional file 1: Table S2). Four patients (9.3%) experi-
enced a total of five SAEs considered to be treatment re-
lated (pleural effusion [two patients; one each in the 100
and 200 mg QD cohorts], tumor lysis syndrome and con-
gestive heart failure [one patient; 400 mg QD cohort], and
diarrhea [one patient; 600 mg QD cohort]). All treatment-
related SAEs resolved with supportive care. Fourteen pa-
tients (32.6%) in phase 1 died during study participation
(10 with MF and four with AML). Seven deaths (involving
four patients with MF and three with AML) were attributed
to AEs (subdural hematoma, intracranial hemorrhage, sep-
tic shock, asthenia, cardiorespiratory arrest, anemia, and
AML; Additional file 1: Table S2). None of the AEs were
considered to be related to treatment. After the 30-day
post-treatment discontinuation follow-up, four patients










100 mg 3 0
150 mg 6 1
(16.7)
Grade 3 ECG QT prolonged from days 18–
47
Resolved following pacritinib discontinuation.
200 mg 9a 0
300 mg 6 1
(16.7)
Grade 3 diarrhea on days 3–4. Resolved following interruption of pacritinib and treatment with
antidiarrheal medication. Pacritinib was restarted.
400 mg 6 0
500 mg 7 1
(14.3)
Grade 2 diarrhea on days 8–140. Resolved following dose reduction to 400 mg and treatment with
antidiarrheal medication.
600 mg 6 2
(33.3)
Grade 3 diarrhea beginning on day 11. Pacritinib was interrupted then reduced to 400 mg. Antidiarrheal medication
was started. Diarrhea was ongoing at the end of treatment.
Grade 1 nausea; grade 1 vomiting; grade 2
dizziness, grade 2 gait disturbance, grade 2
performance status decreased, grade 2
vision blurred
Pacritinib was interrupted then reduced to 400 mg. Nausea and vomiting
resolved with antiemetic therapy after ~85 days; dizziness resolved after
49 days; performance status decrease resolved after 4 days. Gait disturbance
and vision blurred were ongoing at the end of treatment.
aThis cohort included three patients treated with the pacritinib HCl salt formulation and an additional six patients treated with the citrate salt formulation. The
two salt forms have been shown to be pharmaceutically equivalent
DLT dose-limiting toxicity, ECG electrocardiogram
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died due to disease progression and three died due to un-
known causes.
Pharmacokinetics
Pacritinib PK values are shown in Additional file 1: Tables
S3 and S4. Median time to maximum concentration
(Tmax) values ranging from 4 to 8 h post dose and 2.5 to 5
h post dose were reported on days 1 and 15, respectively.
On day 1, mean maximum concentration (Cmax), trough
concentration (C24) and systemic exposure of pacritinib
(AUC0–24) generally increased in a dose-related manner;
however, increases in exposure appeared to be less than
dose-proportional, with systemic exposure appearing to
plateau beyond the 400 mg dose level. On day 15, mean
Cmax, C24 and AUC0–24 did not appear to increase in a
dose-related manner within the 100–300 mg dose range
and, while exposure was higher at the 400 mg dose level
relative to the 300 mg dose level, it appeared to plateau
above the 400 mg dose level. The between-patient coeffi-
cient of variation for Cmax and AUC0–24 ranged from 25
to 63% on day 1 and 20–54% on day 15, indicating rela-
tively high variability across patients.
Table 3 Treatment-emergent adverse events occurring in ≥10% of patients in phase 1 (n = 43)
Treatment-emergent AEs, n (%) 100 mg 150 mg 200 mg 300 mg 400 mg 500 mg 600 mg All patients
n = 3 n = 6 n = 9 n = 6 n = 6 n = 7 n = 6 n = 43
Grade 1/2a Grade 3/4a
Any AE 3 (100.0) 6 (100.0) 9 (100.0) 6 (100.0) 6 (100.0) 7 (100.0) 6 (100.0) 8 (18.6) 35 (81.4)
Diarrhea 2 (66.7) 2 (33.3) 5 (55.6) 3 (50.0) 6 (100.0) 7 (100.0) 6 (100.0) 28 (65.1) 3 (7.0)
Nausea 0 1 (16.7) 2 (22.2) 3 (50.0) 4 (66.7) 5 (71.4) 4 (66.7) 19 (44.2) 0
Vomiting 0 1 (16.7) 4 (44.4) 2 (33.3) 3 (50.0) 3 (42.9) 3 (50.0) 16 (37.2) 0
Fatigue 1 (33.3) 1 (16.7) 3 (33.3) 2 (33.3) 2 (33.3) 3 (42.9) 1 (16.7) 9 (20.9) 4 (9.3)
Edema peripheral 2 (66.7) 2 (33.3) 1 (11.1) 0 2 (33.3) 2 (28.6) 3 (50.0) 10 (23.3) 2 (4.7)
Pyrexia 1 (33.3) 2 (33.3) 2 (22.2) 1 (16.7) 2 (33.3) 2 (28.6) 2 (33.3) 9 (20.9) 3 (7.0)
Anemia 0 1 (16.7) 1 (11.1) 1 (16.7) 2 (33.3) 2 (28.6) 3 (50.0) 3 (7.0) 7 (16.3)
Constipation 2 (66.7) 2 (33.3) 2 (22.2) 1 (16.7) 2 (33.3) 1 (14.3) 1 (16.7) 11 (25.6) 0
Abdominal distension 0 0 2 (22.2) 1 (16.7) 3 (50.0) 1 (14.3) 2 (33.3) 9 (20.9) 0
Dyspnea 2 (66.7) 1 (16.7) 0 0 2 (33.3) 1 (14.3) 3 (50.0) 9 (20.9) 0
Asthenia 2 (66.7) 2 (33.3) 1 (11.1) 0 0 1 (14.3) 2 (33.3) 6 (14.0) 2 (4.7)
Decreased appetite 2 (66.7) 2 (33.3) 0 0 3 (50.0) 0 1 (16.7) 8 (18.6) 0
Epistaxis 2 (66.7) 1 (16.7) 1 (11.1) 2 (33.3) 1 (16.7) 0 1 (16.7) 7 (16.3) 1 (2.3)
Thrombocytopenia 1 (33.3) 2 (33.3) 0 1 (16.7) 2 (33.3) 1 (14.3) 1 (16.7) 2 (4.7) 6 (14.0)
Abdominal pain 1 (33.3) 1 (16.7) 1 (11.1) 1 (16.7) 2 (33.3) 0 1 (16.7) 6 (14.0) 1 (2.3)
Back pain 1 (33.3) 2 (33.3) 0 1 (16.7) 2 (33.3) 1 (14.3) 0 7 (16.3) 0
Insomnia 1 (33.3) 1 (16.7) 2 (22.2) 1 (16.7) 1 (16.7) 1 (14.3) 0 7 (16.3) 0
Hyperuricemia 1 (33.3) 1 (16.7) 0 0 0 1 (14.3) 3 (50.0) 5 (11.6) 1 (2.3)
Cardiac murmur 1 (33.3) 0 1 (11.1) 0 1 (16.7) 1 (14.3) 2 (33.3) 6 (14.0) 0
Dizziness 0 0 2 (22.2) 1 (16.7) 1 (16.7) 1 (14.3) 1 (16.7) 6 (14.0) 0
Night sweats 1 (33.3) 0 1 (11.1) 0 2 (33.3) 1 (14.3) 1 (16.7) 6 (14.0) 0
Neutropenia 1 (33.3) 2 (33.3) 0 1 (16.7) 1 (16.7) 0 0 2 (4.7) 3 (7.0)
Chills 0 2 (33.3) 0 0 1 (16.7) 1 (14.3) 1 (16.7) 5 (11.6) 0
Cough 1 (33.3) 1 (16.7) 1 (11.1) 1 (16.7) 1 (16.7) 0 0 5 (11.6) 0
Dehydration 0 1 (16.7) 0 0 2 (33.3) 1 (14.3) 1 (16.7) 5 (11.6) 0
Hyperbilirubinemia 1 (33.3) 1 (16.7) 1 (11.1) 1 (16.7) 1 (16.7) 0 0 5 (11.6) 0
Pain in extremity 3 (100.0) 0 0 1 (16.7) 0 0 1 (16.7) 5 (11.6) 0
Petechiae 2 (66.7) 2 (33.3) 0 0 0 1 (14.3) 0 5 (11.6) 0
Skin lesion 0 4 (66.7) 1 (11.1) 0 0 0 0 5 (11.6) 0
Upper respiratory tract infection 0 2 (33.3) 2 (22.2) 1 (16.7) 0 0 0 5 (11.6) 0
aWorst grade during treatment
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The mean PK profiles of pacritinib when dosed as citrate
and HCl salts were similar (Additional file 1: Figure S1).
Efficacy
The clinical benefit rate was 94.4% (34/36) in patients
with MF and 42.9% (3/7) in patients with AML, giving
an overall clinical benefit rate of 86.0% (13 patients
achieving clinical improvement and 24 patients having
SD). One patient was reported to have progressive dis-
ease, and disease response was not reported for five pa-
tients. No clear dose–response correlation was observed.
Phase 2
Patients
Thirty-three patients with MF were enrolled in phase
2, 31 of whom received at least one dose of pacritinib
400 mg QD. Patient demographics and baseline char-
acteristics are shown in Table 4. All patients had
splenomegaly with a median length below the left
costal margin (as determined by physical examination)
of 19 cm (range 7–29). At baseline, grade 2 or higher
anemia and thrombocytopenia were reported in 20
(60.6%) and 11 (33.3%) patients, respectively. Six pa-
tients (19.4%) were red blood cell (RBC) transfusion
dependent at baseline and ten patients (33.3%) had re-
ceived RBC transfusions within the 180 days prior to
study entry. No patients were considered platelet
transfusion dependent at baseline, but one patient had
received platelet transfusions within 180 days prior to
study enrollment. Of the 33 patients enrolled, 13
(39.4%) completed the study and 20 patients (60.6%)
discontinued the study prior to completion, primarily
because of the sponsor’s decision to terminate the
study (n = 12) and subject withdrawal of consent (n = 5).
Of the 31 patients who received at least one dose of
pacritinib, median duration of treatment was 11.5 months
(range 1.0–20.1). Median actual dose intensity was
371 mg/day (range 208–400) and relative dose intensity
was 92.9% (range 52.1–100.0%).
Efficacy
Spleen responses are summarized for the efficacy
evaluable population (Table 5) and displayed as median
percent change from baseline up to week 60 (Fig. 1).
The primary endpoint (proportion of evaluable patients
achieving ≥35% spleen volume reduction at week 24 by
MRI) was 23.5% (4/17), with 47.4% (9/19) achieving a
≥50% spleen length reduction at week 24 by physical
examination. When assessed up to the end of treat-
ment, 30.4% of patients (7/23) achieved the objective
spleen volume reduction and 38.7% (12/31) achieved
the objective spleen length reduction. Of the 31 pa-
tients who received at least one dose of pacritinib, 14
were not evaluable for spleen response at week 24: 11
discontinued pacritinib prior to week 24 (seven due to
lack of response, one due to AEs, and one each due to
disease progression, death, and withdrawal of consent)
and three remained on pacritinib after week 24, but did
not complete the week 24 MRI.
At week 24, 38.9% of evaluable patients (7/18) had
achieved a ≥50% reduction in MF Quality of Life and
Symptom Assessment total score relative to baseline
(Table 5). Improvement was seen in each of the individ-
ual symptoms, as well as the overall quality of life score
(Additional file 1: Table S5).
Safety
Thirty-one patients were included in the safety popula-
tion. Table 6 summarizes common treatment-emergent
AEs occurring in ≥10% of patients. Gastrointestinal
toxicities were reported by all patients. No leukopenia,
neutropenia, or lymphopenia was reported during the
study. Twenty-two patients (71.0%) reported at least
one grade 3/4 AE, most frequently anemia (n = 5), diar-
rhea (5), fatigue (5), and bone pain (4). Grade 3 or 4
thrombocytopenia was reported in three patients. One
patient with post-PV MF reported two AEs of pancyto-
penia, grade 3 and 4 in severity, that were considered
unrelated to study drug and resolved. Three patients
(9.7%) discontinued pacritinib because of an AE (grade
2 diarrhea, grade 3 diarrhea, and grade 2 anemia). Four-
teen patients had dose interruptions and 14 patients
had dose reductions because of AEs, most frequently
related to diarrhea.
The most frequent AEs considered to be treatment
related were diarrhea (n = 28; 90.3%), nausea (15; 48.4%),
vomiting (9; 29.0%), and fatigue (4; 12.9%). Grade 3
treatment-related AEs were reported in seven patients
(22.6%), four of which were diarrhea. No grade 4
treatment-related AEs were reported.
Change over time in hematologic parameters is shown
in Additional file 1: Table S6. The percentage change in
hemoglobin measurements at each study visit through
week 60 relative to baseline remained between a median
of −0.5% and +10.1% (range −31% to +146%). At week
24, 10/20 patients (50.0%) had hemoglobin levels <10 g/
L and 1/20 patients (5.0%) had hemoglobin levels <8 g/
L. During the study, 16 patients (51.6%) received RBC
transfusions (median 11 units, range 2–73 units). Plate-
let counts changed modestly on treatment, with a base-
line median platelet count of 126 × 109/L and ranging
from a median of 89 to 155 × 109/L through week 60
on study. At week 24, 10/20 patients (50.0%) and 2/20
patients (10.0%) had platelet counts <100 × 109/L and
<50 × 109/L, respectively. During the study, three pa-
tients (9.7%) received platelet transfusions (median 3
units, range 2–38 units). At week 24, 2/20 patients
(10.0%) had leukocyte counts >25 × 109/L. The median
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neutrophil count was 6.98 x 109/L at baseline and the
median ranged from 3.83 to 6.00 × 109/L through week
60 on study.
SAEs occurred in 13 patients (41.9%), two of which
were considered to be related to pacritinib (grade 3
diarrhea and grade 3 dehydration; Additional file 1:
Table S7). Nine patients (27.3%) who participated in the
phase 2 study died, three during the study due to AEs.
One patient died from disease progression after the 30-
day follow-up and five died due to unknown causes after
the 30-day follow-up. None of the deaths were considered
related to pacritinib (Additional file 1: Table S7).
Discussion
This multicenter phase 1/2 study has provided proof-of-
concept for selective JAK2/FLT-3 inhibition with pacritinib
as a treatment strategy in MF. Patients treated with pacri-
tinib demonstrated notable reductions in spleen volume
and improvements in MF-related symptoms, consistent
with findings of another phase 2 study of pacritinib in
MF [25] and a phase 3 randomized controlled trial com-
paring pacritinib with best-available therapy (PERSIST-1)
[26, 27]. While the pathogenesis of this disease is complex,
it appears that JAK inhibition reduces the inflammatory
and proliferative phenotype associated with JAK/STAT-
signaling aberrancy [28]. Indeed, the improvements in
constitutional symptoms seen with pacritinib in this
study are indicative that suppression of JAK2 even in
the absence of JAK1 blockade is sufficient for inhibition
of the inflammatory cytokine pathway responsible for
disease symptoms.
In the dose-escalation phase of the study, the MTD was
determined to be 500 mg/day, but due to increased toler-
ability, the recommended daily dose of pacritinib to be taken
forward into phase 2 clinical development was 400 mg. This
Table 4 Baseline characteristics and demographics for patients
enrolled in phase 2 (n = 33)a
Pacritinib 400 mg
n = 33b
Median age, years (range) 67.0 (47–83)
Male, n (%) 22 (66.7)
Median time from initial diagnosis, months (range) 31.8 (0.3–210.0)
Median prior systemic therapies, n (range) 1 (0–4)
Median time since last MF treatmentc, months (range) 1.68 (0.6-36.4)




JAK2 mutationd, n (%) 27 (81.8)
Type of myelofibrosis, n (%)
Primary myelofibrosis 17 (51.5)
Post-polycythemia vera myelofibrosis 12 (36.4)
Post-essential thrombocythemia myelofibrosis 4 (12.1)
Current Lille Score, n (%)
High risk 1 (3.0)
Intermediate risk 7 (21.2)
Low risk 2 (6.1)
Missinge 23 (69.7)
Current DIPSS risk category, n (%)
High risk 7 (21.2)
Intermediate-2 risk 9 (27.3)
Intermediate-1 risk 3 (9.1)
Indeterminatef 14 (42.4)
Hemoglobin
Mediang, g/L (range) 90.0 (37–144)
Grade 0–2, n (%) 27 (81.8)
Grade 3, n (%) 6 (18.2)
Baseline hemoglobin level, n (%)
<10 g/L 20 (60.6)
<8 g/L 6 (18.2)
RBC-transfusion dependentg, n (%) 6 (19.4)
Platelets
Mediang, ×109/L (range) 126.0 (28–494)
Grade 0–2, n (%) 29 (87.9)
Grade 3, n (%) 4 (12.1)
Baseline platelet count, n (%)
<100 × 109/L 10 (42.4)
<50 × 109/L 4 (12.1)
Platelet-transfusion dependentg, n (%) 0
Table 4 Baseline characteristics and demographics for patients
enrolled in phase 2 (n = 33)a (Continued)
Leukocytes
Mediang, ×109/L (range) 8.91 (1.5–38.2)
Grade 0–2, n (%) 31 (93.9)
Grade 3, n (%) 2 (6.1)
Baseline leukocyte count >25 × 109/L, n (%) 3 (9.1)
aTwo patients enrolled in the study did not receive the study drug: one
patient withdrew consent before beginning treatment and the second
patient was unable to undergo magnetic resonance imaging (one of the
eligibility criteria)
b97% of patients were white
cIn patients who had received prior treatment (n = 25)
dAll JAK2 mutations were V617F
eCase report forms were designed for direct entry of Lille score by sites; however,
some versions of the forms were missing the field for entry of Lille score
fUnable to calculate DIPSS risk category due to missing baseline peripheral
blood blasts
gIn the safety population (n = 31)
DIPSS Dynamic International Prognostic Scoring System, ECOG PS Eastern
Cooperative Oncology Group Performance Status
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Table 5 Summary of best spleen response and symptom score change from baseline in phase 2 (efficacy evaluable population)a
Endpoint Patients achieving endpoint, n/N (%)
95% CI
At week 24 visit Up to week 24 visit At end of treatment Up to end of treatment
≥35% spleen volume reduction by MRI 4/17 (23.5) 5/23 (21.7) 4/23 (17.4) 7/23 (30.4)
95% CI 6.8–49.9 95% CI 5.0–38.8
≥50% spleen length reduction by physical examination 9/19 (47.4) 12/31 (38.7) 9/31 (29.0) 12/31 (38.7)
95% CI 24.4–71.1 95% CI 14.2–48.0
≥50% reduction in MF Quality of Life and Symptom
Assessment total symptom score
7/18 (38.9) 12/29 (41.4) 4/29 (13.8) 12/29 (41.4)
aPatients included in the efficacy evaluable population are those who had both a non-missing baseline measurement and post-baseline measurement at or
through the time point specified
MRI magnetic resonance imaging
Fig. 1 Median percent change in (a) spleen volume and (b) spleen length from baseline in efficacy evaluable population of the phase 2 study
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is consistent with the PK profile of pacritinib, where expos-
ure began to plateau at the 400 mg dose.
Pacritinib had an acceptable tolerability profile in this
study, with the most common AEs being gastrointestinal
disorders, most of which were grade 1 or 2 in severity
and resolved with treatment interruptions/dose reductions
and supportive care. Gastrointestinal disorders (diarrhea)
accounted for treatment discontinuations in only two
patients. Of particular interest was the low rate of
treatment-emergent anemia or thrombocytopenia during
pacritinib treatment, despite no exclusion from participa-
tion based on baseline hemoglobin level or platelet count.
This is consistent with results from the phase 3 PERSIST-
1 study, which showed that pacritinib resulted in durable
reductions in spleen volume and symptom burden, includ-
ing in patients with baseline thrombocytopenia [29].
This study was terminated by the sponsor (S*BIO Pte
Ltd, Singapore) for financial reasons in October 2011,
meaning that only the data fields assessed as critical for
evaluation of efficacy and safety were queried for missing,
incorrect or discrepant data prior to database lock. This
early termination required all patients who were still re-
ceiving pacritinib to stop, limiting our ability to fully assess
the long-term effects of pacritinib exposure.
JAK kinase inhibitors have shown the potential to
produce durable responses and improve survival in MF
[30, 31]; however, minimizing toxicity and avoiding
drug resistance are ongoing challenges. Indeed, options
remain limited for patients with thrombocytopenia,
who are not suitable for treatment with the only currently
licensed JAK inhibitor, ruxolitinib. These results suggest
that pacritinib has unique characteristics, namely a lack
of substantial myelosuppression and manageable non-
hematological side effects.
Conclusions
In this study, pacritinib demonstrated clinical activity in
patients with MF that had relapsed or that was poorly
controlled with or not suitable for standard therapy. The
lack of substantial myelosuppression and manageable
side effects seen with pacritinib make it an attractive tar-
get for further development in MF.
Additional files
Additional file 1: Table S1. Dose adjustment and toxicity management
guidelines—non-hematologic toxicities. Table S2 Serious adverse events
and deathsa occurring in phase 1 component of the study (n = 43). Table
S3 Day 1 pharmacokinetics of pacritinib in the phase 1 part of the study
(n = 43). Table S4 Day 15 pharmacokinetics of pacritinib in the phase 1
part of the study (n = 43). Table S5 Percent change from baseline at
week 24 for individual and total symptom scores from the Myelofibrosis
Quality of Life and Symptom Assessment Tool—phase 2 (efficacy
Table 6 Treatment-emergent adverse events occurring in ≥10% of patients in phase 2 (n = 31)
Treatment-emergent AEs, n (%) Grade 1 Grade 2 Grade 3 Grade 4 Any grade
Diarrhea 14 (45.2) 9 (29.0) 5 (16.1) 0 28 (90.3)
Fatigue 2 (6.5) 11 (35.5) 4 (12.9) 1 (3.2) 18 (58.1)
Nausea 9 (29.0) 6 (19.4) 1 (3.2) 0 16 (51.6)
Edema peripheral 6 (19.4) 5 (16.1) 1 (3.2) 0 12 (38.7)
Vomiting 7 (22.6) 3 (9.7) 1 (3.2) 0 11 (35.5)
Abdominal pain 3 (9.7) 3 (9.7) 3 (9.7) 0 9 (29.0)
Insomnia 7 (22.6) 2 (6.5) 0 0 9 (29.0)
Pruritus 4 (12.9) 4 (12.9) 1 (3.2) 0 9 (29.0)
Pain in extremity 5 (16.1) 2 (6.5) 0 1 (3.2) 8 (25.8)
Night sweats 4 (12.9) 3 (9.7) 0 0 7 (22.6)
Anemia 0 1 (3.2) 3 (9.7) 2 (6.5) 6 (19.4)
Bone pain 1 (3.2) 1 (3.2) 4 (12.9) 0 6 (19.4)
Asthenia 4 (12.9) 1 (3.2) 0 0 5 (16.1)
Constipation 5 (16.1) 0 0 0 5 (16.1)
Dyspnea 4 (12.9) 0 1 (3.2) 0 5 (16.1)
Cardiac murmur 0 4 (12.9) 0 0 4 (12.9)
Hyperuricemia 2 (6.5) 0 0 2 (6.5) 4 (12.9)
Pyrexia 4 (12.9) 0 0 0 4 (12.9)
Rash 2 (6.5) 1 (3.2) 1 (3.2) 0 4 (12.9)
Upper respiratory tract infection 3 (9.7) 1 (3.2) 0 0 4 (12.9)
Weight decreased 4 (12.9) 0 0 0 4 (12.9)
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evaluable population). Table S6 Median percent change from baseline
in hematologic parameters over time in the phase 2 component of the
study (n = 31). Table S7 Serious adverse events and deathsa occurring
in the phase 2 component of the study (n = 31). Figure S1 Mean
concentration-time profiles of pacritinib when dosed as hydrochloride
and citrate salts at a dose of 200 mg. (DOC 296 kb)
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